Application of Bioregulating Therapy in Complex Treatment of Temporomandibular Joint Diseases
Rybalchenko O.V., Khavinson V.K.
Saint Petersburg Institute of Bioregulation and Gerontology
Advances in Gerontology 25(1): 181-186
Abstract
Diseases of the temporomandibular joint (TMJ) are common in elderly patients, often associated with osteoarthritis and cartilage degeneration. This study evaluated the efficacy of Sigumir (cartilage peptide bioregulator) in the complex treatment of TMJ diseases. Patients received Sigumir in addition to standard therapy. The results showed that the inclusion of Sigumir significantly alleviated pain syndrome, increased the amplitude of mouth opening, and improved chewing function compared to controls. The duration of treatment was shortened, and the frequency of relapses was reduced. The study suggests that Sigumir stimulates the regeneration of fibrocartilaginous tissues of the TMJ and normalizes metabolic processes in the joint structures.
Study Population
Elderly and senile patients (60-85 years) with TMJ osteoarthritis and dysfunction
Context
Temporomandibular joint (TMJ) disorders affect chewing, speaking, and quality of life, especially in the elderly where cartilage degeneration (osteoarthritis) is common. Standard treatments often focus only on symptom relief.
Study Design
Elderly patients with TMJ osteoarthritis received Sigumir (cartilage peptide complex) alongside standard therapy (physiotherapy, NSAIDs) to evaluate its regenerative potential.
Results
Pain Relief
Patients receiving Sigumir reported faster and more complete pain relief compared to the control group. 82% achieved significant pain reduction vs. 54% in controls.
Functional Improvement
- Mouth Opening: The range of motion increased significantly (+8mm), allowing for normal eating and speaking.
- Chewing Efficiency: Objective tests showed a 45% improvement in chewing function.
Long-Term Benefits
At 6-month follow-up, the Sigumir group had a 3x lower relapse rate (12% vs. 38%), suggesting structural improvement in the joint tissues rather than just temporary analgesia.
Mechanism
Sigumir is believed to stimulate the synthesis of collagen and proteoglycans in cartilage cells (chondrocytes), promoting the repair of the fibrocartilaginous disc and articular surfaces of the TMJ.
Significance
This study highlights the potential of Sigumir as a chondroprotective agent that can improve quality of life in elderly patients with degenerative joint diseases.
Statistical Results
Pain reduction: 82% of Sigumir patients vs. 54% controls (p<0.05). Mouth opening amplitude: +8mm vs. +3mm (p<0.01). Chewing efficiency: Improved by 45% vs. 20% (p<0.05). Relapse rate at 6 months: 12% vs. 38% (p<0.05).
Study Limitations
- •Small sample size
- •Single-center study
- •Subjective pain assessment
- •Lack of MRI confirmation of cartilage regeneration
Adverse Events
- •No adverse events reported
- •Well tolerated in elderly patients
Key Findings
- ✓Effective pain reduction in TMJ osteoarthritis
- ✓Improved joint mobility and function
- ✓Reduced relapse rate
- ✓Safe for elderly patients
Mechanism of Action
Stimulation of chondrocyte metabolism, enhanced synthesis of collagen and glycosaminoglycans, and regulation of inflammation in joint tissues.